Omnis Pharma and Magnis Therapeutics Merge to Form Vyriad, a Clinical-Stage Oncolytic Immunovirotherapy Development Company

ROCHESTER, Minn. March 18, 2016 Omnis Pharma, Inc. and Magnis Therapeutics, LLC, announced today their strategic merger to form Vyriad, a clinical-stage oncolytic immunovirotherapy development company. The combined companies’ product development pipeline encompasses multiple clinical-stage and late preclinical-stage products targeting a broad range of human cancer indications, including a Phase 1 development program partnered with a large pharmaceutical company. Financial details of the transaction were not disclosed.

“I am delighted to announce the completion of this merger, which consolidates two leading oncolytic platforms, a broad intellectual property portfolio, a strong collaborative research and development network, and a vibrant clinical-stage product pipeline that spans the cancer spectrum,” said Stephen J. Russell, MD, PhD, President and CEO of Vyriad. “Given our broad clinical and advanced preclinical portfolio, product development engine, and scientific capabilities, I firmly believe that Vyriad is on course to become the leading oncolytic virotherapy company creating powerful new immunotherapies for patients with cancer.”

The combined company results in:

Contact

Mary Moynihan
M2Friend Biocommunications
(802) 951-9600
mary@m2friend.com